Protocols
IIT-CHAUDHARY-PD1-CEMIPLIMAB Phase II OPEN TO ACCRUAL
Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy